SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists. Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing support for emerging research areas for new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment as well as consistent research and development processes for novel drug molecules are important drivers for global lupus erythematous market. Additionally, safety and quality of systemic lupus erythematous controlling therapy may possibly be a challenge for the growth of the global systemic lupus erythematous drugs market. Moreover, numerous public awareness programs targeted to increase awareness levels are also being accompanied. For instance, Lupus?Foundation of America (LFA) has been implementing various projects to increase central support for SLE research and services to support people and families affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for new treatment options with better levels of efficacy and safety are obstructing the global systemic lupus erythematous drugs market. In 2019, the market size of Systemic Lupus Erythematosus (SLE) Drugs is 170 million US$ and it will reach 280 million US$ in 2025, growing at a CAGR of 6.8% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Systemic Lupus Erythematosus (SLE) Drugs. This report studies the global market size of Systemic Lupus Erythematosus (SLE) Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia). This study presents the Systemic Lupus Erythematosus (SLE) Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019. In global market, the following companies are covered: Anthera Pharmaceuticals GSK ImmuPharma Johnson & Johnson ... Market Segment by Product Type Corticosteroids Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Anti-Inflammatories Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Antimalarials BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS) Immunosuppressive Agents/Immune Modulators Anticoagulants Market Segment by Application Intravenous Sub-Cutaneous Oral Topical Key Regions split in this report: breakdown data for each region. United States China European Union Rest of World (Japan, Korea, India and Southeast Asia) The study objectives are: To analyze and research the Systemic Lupus Erythematosus (SLE) Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast. To present the key Systemic Lupus Erythematosus (SLE) Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players. To split the breakdown data by regions, type, companies and applications To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. To identify significant trends, drivers, influence factors in global and regions To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market In this study, the years considered to estimate the market size of Systemic Lupus Erythematosus (SLE) Drugs are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025
Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Major Manufacturers Covered in This Report 1.3 Market Segment by Type 1.3.1 Global Systemic Lupus Erythematosus (SLE) Drugs Market Size Growth Rate by Type (2019-2025) 1.3.2 Corticosteroids 1.3.3 Non-Steroidal Anti-inflammatory Drugs (NSAIDs) 1.3.4 Anti-Inflammatories 1.3.5 Diseas
